Mushood Ahmed (@mushoodch) 's Twitter Profile
Mushood Ahmed

@mushoodch

MS-5/Clinical Researcher

ID: 1801210975615410176

calendar_today13-06-2024 11:12:27

39 Tweet

82 Takipçi

548 Takip Edilen

Sivaram Neppala, MD, PhD (@sivaramneppala) 's Twitter Profile Photo

📢 Publication Announcement I’m pleased to share our recent work, now available in press in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI) SCAI 🔍 Title: 🫀Trends and Disparities in Cardiogenic Shock Mortality Among Adults with Acute

📢 Publication Announcement
I’m pleased to share our recent work, now available in press in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI) <a href="/SCAI/">SCAI</a> 

🔍 Title:
🫀Trends and Disparities in Cardiogenic Shock Mortality Among Adults with Acute
Jamal Rana, MD (@jamalranamd) 's Twitter Profile Photo

Our paper out today in International Journal of Cardiology Heart&Vasc led by a super ⭐️ team! ⚡️In past 25 years #CardiogenicShock related mortality in heart failure team has increased nearly 4 fold! 💔 ⚡️Mortality notably higher in #rural areas.

Our paper out today in <a href="/IJC_Heart_Vasc/">International Journal of Cardiology Heart&Vasc</a>  led by a super ⭐️ team! 
⚡️In past 25 years #CardiogenicShock related mortality in heart failure team has increased nearly 4 fold! 💔
⚡️Mortality notably higher in #rural areas.
Mushood Ahmed (@mushoodch) 's Twitter Profile Photo

Our new publication in RPTH ! 🩸 Reduced-dose DOACs for extended #VTE treatment ⚖️ Similar efficacy to full-dose 🛡️ Lower bleeding risk (29%↓ major bleeds) 🔗 Full study: sciencedirect.com/science/articl… Raheel Ahmed Jamal Rana, MD Steve Greene Marat Fudim, MD MHS Robert Mentz, MD Gregg Fonarow MD

Our new publication in
<a href="/RPTHjournal/">RPTH</a> !
🩸 Reduced-dose DOACs for extended #VTE treatment
⚖️ Similar efficacy to full-dose
🛡️ Lower bleeding risk (29%↓ major bleeds)

🔗 Full study: sciencedirect.com/science/articl…

<a href="/RaheelA29288418/">Raheel Ahmed</a>
<a href="/JamalRanaMD/">Jamal Rana, MD</a>
<a href="/SJGreene_md/">Steve Greene</a>
<a href="/FudimMarat/">Marat Fudim, MD MHS</a>
<a href="/robmentz/">Robert Mentz, MD</a>
<a href="/gcfmd/">Gregg Fonarow MD</a>
Tallal Hashmi (@hashmit338) 's Twitter Profile Photo

Intravenous thrombolysis prior to mechanical thrombectomy demonstrated comparable outcomes to thrombectomy alone in terms of functional recovery, recanalization, mortality, and hemorrhage. Ameer E. Hassan Gregg Fonarow MD Raheel Ahmed Mushood Ahmed Muhammad Shakir

Intravenous thrombolysis prior to mechanical thrombectomy demonstrated comparable outcomes  to thrombectomy alone in terms of functional recovery, recanalization, mortality, and hemorrhage.

<a href="/AmeerEHassan/">Ameer E. Hassan</a>
<a href="/gcfmd/">Gregg Fonarow MD</a> 
<a href="/RaheelA29288418/">Raheel Ahmed</a> 
<a href="/MushoodCh/">Mushood Ahmed</a> 
<a href="/ShakirMbbs/">Muhammad Shakir</a>
Jamal Rana, MD (@jamalranamd) 's Twitter Profile Photo

Our #editorial - Time to Disaggregate #AsianAmerican to Address Disparities in Heart Failure Risk in JACC Journals out. ⚡️For context the term #Asians typically refers to people originating from continent of Asia, which includes East, Southeast, South, Central, and West Asia,

Our #editorial - Time to Disaggregate #AsianAmerican to Address Disparities in Heart Failure Risk in <a href="/JACCJournals/">JACC Journals</a> out. 
⚡️For context the term #Asians typically refers to people originating from  continent of Asia, which includes East, Southeast, South, Central, and West Asia,
Gregg Fonarow MD (@gcfmd) 's Twitter Profile Photo

Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials - Research and Practice in Thrombosis and Haemostasis rpthjournal.org/article/S2475-… Marat Fudim, MD MHS Robert Mentz, MD

Aimen Shafiq (@aimenshafiq_) 's Twitter Profile Photo

Hi #MedTwitter! I’m a recent #IMG from Pakistan🇵🇰, applying to #InternalMedicine for #Match2026. I’m interested in #cardiology🫀, research🔬, and patient care. Outside of medicine, I love books📚, pools and cats🐈! 👉AAMC ID: 15861876 #residency #womeninmedicine #medicine

Hi #MedTwitter!

I’m a recent #IMG from Pakistan🇵🇰, applying to #InternalMedicine for #Match2026. 

I’m interested in #cardiology🫀, research🔬, and patient care.

Outside of medicine, I love books📚, pools and cats🐈!

👉AAMC ID: 15861876

#residency #womeninmedicine #medicine
Mushood Ahmed (@mushoodch) 's Twitter Profile Photo

Our new publication! 📊 Meta-analysis (8 RCTs, n=2,653) 🩺 ASIs cut systolic BP by −6.0 mmHg 📉 ↘️ Trend to lower diastolic BP (−2.2 mmHg, p=0.06) ⚖️ No ↑ serious AEs, but ⚠️↑ K+ risk 👉 Promising for resistant HTN 💊 🔗 doi.org/10.1002/edm2.7… #Hypertension #CardioResearch

Our new publication!
📊  Meta-analysis (8 RCTs, n=2,653)
🩺 ASIs cut systolic BP by −6.0 mmHg 📉
↘️ Trend to lower diastolic BP (−2.2 mmHg, p=0.06)
⚖️ No ↑ serious AEs, but ⚠️↑ K+ risk
👉 Promising for resistant HTN 💊
🔗 doi.org/10.1002/edm2.7…
#Hypertension #CardioResearch
Mushood Ahmed (@mushoodch) 's Twitter Profile Photo

New publication in AHJPlus 📊 Meta-analysis (16 RCTs, n=20,601) 🩺 Colchicine ↓ MI risk ⚖️ No effect on all-cause/CV death ⚠️ ↑ GI AEs & discontinuations 🔗 doi.org/10.1016/j.ahjo… Jamal Rana, MD Marat Fudim, MD MHS Gregg Fonarow MD

New publication in <a href="/AHJPlus/">AHJPlus</a> 
📊 Meta-analysis (16 RCTs, n=20,601)
🩺 Colchicine ↓ MI risk 
⚖️ No effect on all-cause/CV death
⚠️ ↑ GI AEs &amp; discontinuations
🔗 doi.org/10.1016/j.ahjo…

<a href="/JamalRanaMD/">Jamal Rana, MD</a> <a href="/FudimMarat/">Marat Fudim, MD MHS</a> <a href="/gcfmd/">Gregg Fonarow MD</a>
Gregg Fonarow MD (@gcfmd) 's Twitter Profile Photo

HFrEF Intolerant or contraindication to beta-blockers NSR Ivabradine ➡️ 29% ⬇️ CV☠️/HF🏨 (9.9% ARR, NNT=10) 38% ⬇️ HF🏨 (9.8% ARR) 20% ⬇️ CV☠️ (trend, 5.5% ARR) Cost $22/month Worth it?

HFrEF
Intolerant or contraindication to beta-blockers
NSR

Ivabradine ➡️

29% ⬇️ CV☠️/HF🏨 (9.9% ARR, NNT=10)

38% ⬇️ HF🏨 (9.8% ARR)

20% ⬇️ CV☠️ (trend, 5.5% ARR)

Cost $22/month

Worth it?
Gregg Fonarow MD (@gcfmd) 's Twitter Profile Photo

Just released in Journal of Cardiac Failure - the HFSA HF Stats 2025 report! 📖 Read the report ➡️ onlinejcf.com/article/S1071-… 📺 Watch the highlights ➡️ youtu.be/0fq_wF4IxoU 🎯 Make these data count 👏 Special thanks to the entire writing group #HFStats2025 #heartfailurestats

Just released in <a href="/JCardFail/">Journal of Cardiac Failure</a> - the <a href="/HFSA/">HFSA</a> HF Stats 2025 report!

📖 Read the report ➡️ onlinejcf.com/article/S1071-…

📺 Watch the highlights ➡️ youtu.be/0fq_wF4IxoU

🎯 Make these data count 
 
👏 Special thanks to the entire writing group

#HFStats2025 #heartfailurestats
Gregg Fonarow MD (@gcfmd) 's Twitter Profile Photo

🧪 ~$250 million/year is directed toward HF specific research 📈 Despite its massive health and economic burden, HF receives less funding than cancer or neurological diseases 💰 Economic Burden vs. Research Investment 🚫⚖️ 🚨 Need to better prioritize HF research HFSA

Mushood Ahmed (@mushoodch) 's Twitter Profile Photo

New publication in American Journal of Medicine 📊 Meta-analysis (5 RCTs, n=4,964) 👥 Patients: chronic coronary disease (most post-PCI and with Afib) 💊 OAC monotherapy ↓ bleeding risk ⚖️ No ↑ in MI, stroke, or death 🔗 doi.org/10.1016/j.amjm… Jamal Rana, MD Gregg Fonarow MD

New publication in <a href="/amjmed/">American Journal of Medicine</a> 
📊 Meta-analysis (5 RCTs, n=4,964)
👥 Patients: chronic coronary disease (most post-PCI and with Afib)
💊 OAC monotherapy ↓ bleeding risk
⚖️ No ↑ in MI, stroke, or death

🔗 doi.org/10.1016/j.amjm…
<a href="/JamalRanaMD/">Jamal Rana, MD</a> 
<a href="/gcfmd/">Gregg Fonarow MD</a>
Harlan Krumholz (@hmkyale) 's Twitter Profile Photo

This is an extraordinary report from Institute for Health Metrics and Evaluation (IHME) and published in JACC Journals; it demonstrates that cardiovascular disease is a global scourge. And we are failing to leverage what we know to save lives. jacc.org/doi/10.1016/j.…

This is an extraordinary report from <a href="/IHME_UW/">Institute for Health Metrics and Evaluation (IHME)</a> and published in <a href="/JACCJournals/">JACC Journals</a>; it demonstrates that cardiovascular disease is a global scourge. And we are failing to leverage what we know to save lives. jacc.org/doi/10.1016/j.…
Gregg Fonarow MD (@gcfmd) 's Twitter Profile Photo

Muthu Vaduganathan Steve Greene Andrew J Sauer MD Anu Lala (Anuradha Lala-Trindade) Shelley Zieroth Javed Butler Pedro Schwartzmann, MD, PhD, FESC 🇧🇷 Jonathan Davis, MD, MPHS HFAPresident Ankeet S. Bhatt, MD, MBA BB in-hospital in HFrEF markedly improves use, adherence, persistence, and clinical outcomes including lower all-cause mortality This Rx is the single most effective mortality reducing therapy in 🏨 HFrEF and Class 1 in guidelines across the world for in🏨 use

<a href="/mvaduganathan/">Muthu Vaduganathan</a> <a href="/SJGreene_md/">Steve Greene</a> <a href="/AndrewJSauer/">Andrew J Sauer MD</a> <a href="/dranulala/">Anu Lala (Anuradha Lala-Trindade)</a> <a href="/ShelleyZieroth/">Shelley Zieroth</a> <a href="/JavedButler1/">Javed Butler</a> <a href="/pedschwartzmann/">Pedro Schwartzmann, MD, PhD, FESC 🇧🇷</a> <a href="/JonathanDavisHF/">Jonathan Davis, MD, MPHS</a> <a href="/HFA_President/">HFAPresident</a> <a href="/ankeetbhatt/">Ankeet S. Bhatt, MD, MBA</a> BB in-hospital in HFrEF markedly improves use, adherence, persistence, and clinical outcomes including lower all-cause mortality 

This Rx is the single most effective mortality reducing therapy in 🏨 HFrEF and Class 1 in guidelines across the world for in🏨 use